1.Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease.
Fang Ning YOU ; Liang LUO ; Xiang Jun LIU ; Xue Wu ZHANG ; Chun LI
Journal of Peking University(Health Sciences) 2023;55(6):1045-1052
OBJECTIVE:
To investigate the fetal and maternal outcomes, risk factors of disease progression and adverse pregnancy outcomes (APOs) in patients with undifferentiated connective tissue disease (UCTD).
METHODS:
This retrospective study described the outcomes of 106 pregnancies in patients with UCTD. The patients were divided into APOs group (n=53) and non-APOs group (n=53). The APOs were defined as miscarriage, premature birth, pre-eclampsia, premature rupture of membranes (PROM), intrauterine growth restriction (IUGR), postpartum hemorrhage (PPH), and stillbirth, small for gestational age infant (SGA), low birth weight infant (LBW) and birth defects. The differences in clinical manifestations, laboratory data and pregnancy outcomes between the two groups were compared. Logistic regression analysis was performed to analyze the risk factors for APOs and the progression of UCTD to definitive CTD.
RESULTS:
There were 99 (93.39%) live births, 4 (3.77%) stillbirths and 3 (2.83%) miscarriage, 20 (18.86%) preterm delivery, 6 (5.66%) SGA, 17 (16.03%) LBW, 11 (10.37%) pre-eclampsia, 7 (6.60%) cases IUGR, 19 (17.92%) cases PROM, 10 (9.43%) cases PPH. Compared with the patients without APOs, the patients with APOs had a higher positive rate of anti-SSA antibodies (73.58% vs. 54.71%, P=0.036), higher rate of leukopenia (15.09% vs. 3.77%, P=0.046), lower haemoglobin level [109.00 (99.50, 118.00) g/L vs. 124.00 (111.50, 132.00) g/L, P < 0.001].Multivariate Logistic regression analysis showed that leucopenia (OR=0.82, 95%CI: 0.688-0.994) was an independent risk factors for APOs in UCTD (P=0.042). Within a mean follow-up time of 5.00 (3.00, 7.00) years, the rate of disease progression to a definite CTD was 14.15%, including 8 (7.54%) Sjögren's syndrome, 4 (3.77%) systemic lupus erythematosus (SLE), 4 (3.77%) rheumatoid arthritis and 1 (0.94%) mixed connective tissue disease. Multivariate Cox proportional risk regression analysis showed that Raynaud phenomenon (HR=40.157, 95%CI: 3.172-508.326) was an independent risk factor for progression to SLE.
CONCLUSION
Leukopenia is an independent risk factor for the development of APOs in patients with UCTD. Raynaud's phenmon is a risk factor for the progression of SLE. Tight disease monitoring and regular follow-up are the key measures to prevent adverse pregnancy outcomes and predict disease progression in UCTD patients with pregnancy.
Pregnancy
;
Infant, Newborn
;
Female
;
Humans
;
Pregnancy Outcome
;
Retrospective Studies
;
Abortion, Spontaneous/etiology*
;
Undifferentiated Connective Tissue Diseases
;
Pre-Eclampsia/epidemiology*
;
Lupus Erythematosus, Systemic
;
Risk Factors
;
Leukopenia
;
Pregnancy Complications/epidemiology*
;
Disease Progression
;
Connective Tissue Diseases/epidemiology*
2.Differences in the Adverse Effects of Azathioprine between Inflammatory Bowel Disease and Autoimmune Hepatitis in Korean Patients.
Yoo Jin LEE ; Wang Yong CHOI ; Kyung Sik PARK ; Yun Jung KIM ; Kwang Bum CHO ; Eun Soo KIM ; Byoung Kuk JANG ; Woo Jin CHUNG ; Jae Seok HWANG
The Korean Journal of Gastroenterology 2014;64(6):348-355
BACKGROUND/AIMS: Azathioprine (AZA) has been widely used in the therapy of inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). However, studies evaluating the adverse effects of AZA in these two diseases are lacking. The aim of this study was to compare the adverse effects of AZA in Korean IBD and AIH patients. METHODS: Patients with IBD or AIH who were treated with AZA at Keimyung University Dongsan Medical Center (Daegu, Korea) between January 2002 and March 2011 were enrolled. Their medical records were reviewed retrospectively in terms of clinical characteristics and adverse effects of AZA. RESULTS: A total of 139 IBD patients and 55 AIH patients were finally enrolled. Thirty IBD patients (21.6%) and eight AIH patients (14.5%) experienced adverse effects of AZA. In particular, the prevalence of leukopenia was significantly higher in the IBD group than in the AIH group (p=0.026). T474C mutation was observed in three of 10 patients who were assessed for thiopurine methyltransferase (TPMT) genotype. CONCLUSIONS: IBD patients are at increased risk for the adverse effects of AZA compared with AIH patients, of which leukopenia was the most commonly observed. Therefore, IBD patients receiving AZA therapy should be carefully monitored.
Adolescent
;
Adult
;
Aged
;
Azathioprine/adverse effects/*therapeutic use
;
Base Sequence
;
Female
;
Genotype
;
Hepatitis, Autoimmune/*drug therapy
;
Humans
;
Immunosuppressive Agents/adverse effects/*therapeutic use
;
Inflammatory Bowel Diseases/*drug therapy
;
Leukopenia/epidemiology/etiology
;
Male
;
Methyltransferases/chemistry/genetics
;
Middle Aged
;
Polymorphism, Single Nucleotide
;
Republic of Korea
;
Retrospective Studies
;
Young Adult